secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tilray Brands, Inc. (TLRY)
CIK:        0001731348
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001171843-26-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tilray Brands Q2 FY2026 revenue record $218M; net cash $30M; reaffirms EBITDA guidance
--------------------------------------------------------------------------------

- Net revenue $218M, a record quarterly; international medical cannabis revenue increased 36% YoY.
- Ended quarter with $292M cash and marketable securities; net cash position of approximately $30M.
- Canadian adult-use cannabis revenue grew 6% YoY; Tilray Pharma achieved record quarterly revenue.
- Reaffirmed full-year adjusted EBITDA guidance; Chairman cites disciplined execution and long-term value.
- U.S. federal cannabis rescheduling expected to unlock new market opportunity for Tilray Medical expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/0001171843-26-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1731348/000117184326000146/f8k_010826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer